CNE0000009T3
CNE0000009T3
HARBIN PHARMACEUTICAL GROUP CO
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 15.964.064.819 | 16.175.856.239 | 1.3% |
| Cost of Revenue | 11.815.835.068 | 11.607.227.744 | 1.8% |
| Gross Profit | 4.148.229.751 | 4.568.628.495 | 9.2% |
| 3.417.723.032 | 3.594.153.262 | 4.9% | |
| Operating Income | 730.506.719 | 974.475.233 | 25.0% |
| Pretax Income | 572.738.622 | 875.006.106 | 34.5% |
| Net Income Common Stockholders | 361.597.036 | 628.846.598 | 42.5% |
| -- | -- | -- | |
| -- | -- | -- |